Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Anixa Biosciences Inc ANIX

Healthcare Biotechnology
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well... see more

Recent & Breaking News (NDAQ:ANIX)

Anixa Biosciences Establishes Cancer Business Advisory Board

PR Newswire September 19, 2023

Anixa Biosciences to Participate in September Investor Conferences

PR Newswire August 31, 2023

Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical Trial

PR Newswire August 28, 2023

Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual CAR-TCR Summit

PR Newswire August 14, 2023

Could Anixa Biosciences (NASDAQ:ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?

Accesswire August 10, 2023

Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial

PR Newswire August 7, 2023

Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology

PR Newswire July 27, 2023

Anixa Biosciences Announces Issuance of Canadian Patent for its CAR-T Cancer Therapy Technology

PR Newswire July 11, 2023

Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial

PR Newswire May 22, 2023

Anixa Biosciences Clarifies Poster Presentation on Company Website

PR Newswire April 17, 2023

Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine

PR Newswire April 17, 2023

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2023 AACR Annual Meeting

PR Newswire March 27, 2023

Anixa Biosciences Reassures Shareholders It Has No Accounts at Silicon Valley Bank

PR Newswire March 13, 2023

Anixa Biosciences to Provide Corporate Update at its 2023 Annual Meeting of Stockholders

PR Newswire March 2, 2023

Anixa Biosciences Announces Notice of Allowance of Additional Key Patent on Breast Cancer Vaccine Technology

PR Newswire February 27, 2023

Anixa Biosciences Announces Formation of Breast Cancer Clinical Advisory Board

PR Newswire February 21, 2023

Anixa Biosciences to Present at Biotech Showcase 2023

PR Newswire December 19, 2022

Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine

PR Newswire December 8, 2022

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2022 San Antonio Breast Cancer Symposium

PR Newswire November 8, 2022

Dr. Jose Conejo-Garcia, Invited to Present Keynote Address at Duke Cancer Institute, will Discuss Anixa Biosciences' Ovarian Cancer CAR-T Therapy

PR Newswire October 31, 2022